Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The Genzyme Corp. division develops biotech products for orthopedic procedures. Top sellers include knee osteoarthritis treatment Synvisc and Carticel, which repairs damaged knee cartilage. Genzyme Biosurgery's biosurgical specialties unit makes Seprafilm, which prevents tissue adhesions after surgery. Other products include those to assist in adhesion prevention and hernia repair (Sepramesh) and severe burn treatment (Epicel).

Metabolex, Inc. was founded in 1991 and is based in Hayward, California. Metabolex, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of type II diabetes and related metabolic disorders. The company’s products include MBX-102/JNJ 39659100, an oral small-molecule insulin sensitizer; MBX-8025, which is intended for the treatment of dyslipidemia; MBX-2982, which is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract; and MBX-2044, a second generation insulin sensitizer.

Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas. Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.

Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas. Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

England's Northwest region is a hotbed of biotechnology growth. It's Bionow's job to make the region even hotter -- and turn it into the center of biomanufacturing in Europe. Funded by the Northwest Development Agency, Bionow promotes and encourages growth in the area, which is already home to a plethora of biomanufacturing facilities for companies such as AstraZeneca, Eli Lilly, and Chiron Vaccines. Bionow offers information on companies, facilities, and services in the region, promotes educational and networking events, and organizes overseas trade missions. The Northwest also has several academic research centers in Liverpool and Manchester.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

Cyprotex PLC is a holding company, which is engaged in the provision of in vitro and in silico ADMET/PK (Absorption, Distribution, Metabolism, Excretion, Toxicity/Pharmacokinetic) information to the pharmaceutical industry. The Company developed a suite of services and technologies known as Cloe (Cyprotex Lead Optimisation Engine). It combines in vitro screening with pharmacokinetic prediction system to offer an integrated suite of ADME services to the pharmaceutical and biotechnology companies worldwide. During the year ended December 31, 2008, the Company introduced a new Cloe product line, Cloe Select, which focuses on studies performed of drug discovery or preclinical development stage. Its subsidiaries include Cyprotex Discovery Ltd, Cyprotex Research Ltd and Cyprotex North America, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.